Drug-Induced Ocular Toxicity — Retinal & Optic Nerve

Overview

A short list of systemic drugs — prescribed for common conditions like rheumatoid arthritis, lupus, atrial fibrillation, psychiatric illness, and tuberculosis — are selectively toxic to structures at the back of the eye: the retinal pigment epithelium (RPE) and photoreceptors, or the optic nerve itself. What makes this cluster clinically important is not rarity; hydroxychloroquine alone is taken chronically by hundreds of thousands of patients. What makes it important is that the resulting vision loss is, in most cases, permanent and irreversible once it becomes clinically apparent — there is no antidote, no reversal agent, and no treatment that restores damaged photoreceptors or RPE.

That asymmetry — no fix once damage is visible, but real prevention if damage is caught early — is why this entire topic is organized around monitoring rather than treatment. The ophthalmologist's job for these drugs is almost entirely to detect subclinical toxicity with structural and functional testing before a patient ever notices a visual symptom, so the prescribing physician can stop or adjust the drug while the damage is still preventable. Several of these drugs also share a chemical property — being cationic amphiphilic compounds — that produces a second, unrelated, and far more benign eye finding, which is a common source of confusion worth untangling explicitly.

Clinical Features

Hydroxychloroquine & Chloroquine Retinal Toxicity

Hydroxychloroquine (and, less commonly used today, chloroquine) is prescribed for rheumatoid arthritis, systemic lupus erythematosus, and other autoimmune conditions, often for years to decades. With cumulative use, the drug accumulates in the RPE and photoreceptors, producing damage that classically localizes to the parafoveal retina — sparing the very center of the fovea while destroying the ring immediately around it. On fundus examination or autofluorescence imaging, this produces the disease's signature appearance: a "bull's-eye" maculopathy, a ring of RPE atrophy encircling a relatively preserved central fovea.

The critical clinical point is that by the time a bull's-eye pattern is visible on routine fundus exam, the toxicity is already advanced — and established RPE/photoreceptor loss does not recover even after the drug is stopped. The entire monitoring strategy for this drug (below) exists to identify toxicity at a stage well before it reaches this visible endpoint.

Hydroxychloroquine and chloroquine belong to a drug class called cationic amphiphilic drugs — molecules with both a hydrophilic charged region and a hydrophobic lipid-soluble region, which lets them accumulate inside lysosomes of various tissues. That same class property is what causes a second, separate corneal finding: whorl-like deposits of lipofuscin in the basal corneal epithelium, known as corneal verticillata (or vortex keratopathy). This is a distinct, dose- and duration-dependent phenomenon from the retinal toxicity above — it does not represent early retinal disease, and on its own it rarely affects vision.

Amiodarone-Associated Optic Neuropathy

Amiodarone, an antiarrhythmic used chronically for atrial fibrillation and other arrhythmias, is also a cationic amphiphilic drug and produces corneal verticillata by the same mechanism as hydroxychloroquine and chloroquine above — a third drug sharing that same benign corneal finding.

Amiodarone's more consequential ocular toxicity is a distinct optic neuropathy, thought to result from phospholipidosis (lysosomal lipid accumulation) disrupting axoplasmic transport within optic nerve fibers. The key teaching point is how this presentation differs from classic non-arteritic ischemic optic neuropathy: amiodarone-associated optic neuropathy is typically bilateral and has an insidious, gradual onset with prolonged disc edema, in contrast to the sudden, usually unilateral onset and disc edema that resolves within weeks that is typical of classic ischemic optic neuropathy. That bilateral, slow-onset, long-lasting disc edema pattern is also what distinguishes it from arteritic ischemic optic neuropathy, traumatic optic neuropathy, and compressive optic neuropathy — each of which has its own distinct tempo and laterality.

Thioridazine Pigmentary Retinopathy

Thioridazine is an older antipsychotic (a phenothiazine) whose retinal toxicity is specifically associated with high cumulative doses. It produces a diffuse pigmentary retinopathy: clumped, coarse pigment deposition together with RPE atrophy, sometimes described as a "salt and pepper" fundus appearance. Unlike some of the other entities on this page, thioridazine toxicity can progress rapidly and can continue to worsen even after the drug is discontinued if it isn't caught early — making early detection especially high-stakes for this specific drug.

It's worth contrasting this with lower-dose phenothiazines such as chlorpromazine, which more typically produce anterior segment pigment deposition — in the cornea and lens — rather than the retinal pigmentary toxicity described above. The retinopathy discussed here is a high-cumulative-dose thioridazine phenomenon specifically, not a class effect of every phenothiazine at ordinary doses.

Diagnosis / Monitoring

For hydroxychloroquine and chloroquine, the goal of monitoring is to detect toxicity before it is visible on a dilated fundus exam. Spectral-domain optical coherence tomography (SD-OCT) and visual field testing are the key modalities for this — SD-OCT can reveal early parafoveal photoreceptor and RPE disruption, and visual fields can show early parafoveal scotomas, both preceding any visible bull's-eye change on fundus exam. Because toxicity risk climbs with cumulative dose and duration of therapy, these patients are followed with structured, periodic screening for as long as they remain on the drug.

For ethambutol, monitoring centers on baseline testing before starting therapy and periodic testing during treatment, specifically including visual acuity and color vision testing — because, as described below, this toxicity has a distinctive color vision signature that can be an earlier or more specific signal than acuity alone.

Management

Across this entire drug cluster, there is no treatment that reverses established RPE, photoreceptor, or optic nerve damage — which is exactly why screening is treated as the primary intervention rather than a formality before one. Once toxicity is detected — structurally on OCT, functionally on visual field or color vision testing, or clinically on exam — the standard response is to stop or substitute the offending drug (in coordination with the prescribing physician, since these are often drugs treating serious systemic disease) before damage progresses further.

Ethambutol optic neuropathy is the most favorable of this group prognostically: generally reversible if it is caught early and the drug is discontinued promptly, which is precisely the rationale for baseline and periodic monitoring during tuberculosis treatment. Thioridazine sits at the other end of the spectrum — its pigmentary retinopathy can continue to progress even after the drug is stopped if detection is delayed, underscoring why early, proactive screening matters more for this drug than a "stop and reassess" approach would suggest. Hydroxychloroquine/chloroquine toxicity and amiodarone optic neuropathy fall in between: stopping the drug prevents further progression, but established structural loss does not recover.

Related Topics

Continue exploring Systemic Disease & the Eye: